We assess the prevalence and seriousness of DDIs among ambulatory cancer patients on anti-cancer treatment.
ID
Bron
Verkorte titel
Aandoening
Cancer, chemotherapy, drug-drug interactions, oncology, pharmacology, risk factors.
Ondersteuning
2.Stichting Coolsingel
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Prevalence of drug-drug interactions (DDI's) and the clinical consequence of these DDI's.
Achtergrond van het onderzoek
Drug-drug interactions in patients using anticancer drugs are common, although not always these are recognized by pharmacists and physicians. These interactions may have serious consequences for the number and severity of side-effects and efficacy of treatment. As side-effects could potentially be lethal, and efficacy could be diminished by such interactions, it is extremely important to visualize drug-drug interactions (DDI) on forehand. With a firm increase in available (and chronically used) oral anticancer agents during recent years, the risk for DDIs has become even more important for clinical practice. Outcomes of this study may help physicians and pharmacists to create awareness of DDIs and should lead to a closer collaboration between them to identify and manage these DDIs.
Doel van het onderzoek
We assess the prevalence and seriousness of DDIs among ambulatory cancer patients on anti-cancer treatment.
Onderzoeksopzet
1-2-2012: Start study inclusion;
1-2-2013: End study inclusion;
1-2-2013 till 1-2-2013: Analysing, writing.
Onderzoeksproduct en/of interventie
Medication review in oncology.
Publiek
´s-Gravendijkwal 230
Roelof Leeuwen, van
Rotterdam 3015 CE
The Netherlands
+31 (0)10 7033202
r.w.f.vanleeuwen@erasmusmc.nl
Wetenschappelijk
´s-Gravendijkwal 230
Roelof Leeuwen, van
Rotterdam 3015 CE
The Netherlands
+31 (0)10 7033202
r.w.f.vanleeuwen@erasmusmc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
All ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who are receiving one or more (oral) anti-cancer therapies, are included in the study.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1. The use of experimental trial agents;
2. Age <18 years;
3. The use of anti-cancer drugs for non-malignant diseases.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL3591 |
| NTR-old | NTR3760 |
| Ander register | METC : 12.12151 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd. |